Biolase, Inc. BIOLQ
- Market cap
- $2.3M
- P/E
- 0.0×
Follow BIOLQ
Target Price Range
Analyst price targets
Free account| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | 8,330.94 | 3,500.00 | 2,275.00 | 1,075.00 | 527.50 | 925.00 | 51.30 | 1.07 |
Analyst estimates 2024–2026 Powerpack |
Low Price
|
||
| — | — | 23,232.76 | 21,942.05 | 7,450.00 | 7,175.00 | 2,400.00 | 3,775.00 | 1,175.00 | 76.00 |
High Price
|
|||
| — | — | 225 | 195 | 190 | 157 | 135 | 161 | 192 | 157 |
Employees
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | 52 | 47 | 46 | 38 | 23 | 39 | 48 | 49 |
Revenue
|
|||
| — | — | 39.20% | 32.23% | 36.60% | 37.80% | 27.10% | 42.18% | 32.83% | 34.02% |
Gross Margin
|
|||
| — | — | (15) | (17) | (21) | (18) | (17) | (16) | (29) | (21) |
EBT
|
|||
| — | — | (29.38%) | (37.15%) | (46.48%) | (47.35%) | (73.31%) | (41.07%) | (58.86%) | (41.90%) |
EBT Margin
|
|||
| — | — | (15) | (17) | (22) | (18) | (17) | (16) | (29) | (21) |
Net Income
|
|||
| — | — | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 |
Depreciation
|
|||
| — | — | 10,573.47 | 7,953.56 | 5,628.66 | 4,064.41 | 929.80 | 664.20 | 702.35 | 38.47 |
Revenue/Sh
|
|||
| — | — | (3,625.00) | (3,500.00) | (2,625.00) | (1,925.00) | (1,400.00) | (275.00) | (416.00) | (29.44) |
Earnings/Sh
|
|||
| — | — | (2,162.45) | (3,120.68) | (1,725.24) | (1,370.54) | (522.24) | (283.22) | (387.84) | (11.03) |
Cash Flow/Sh
|
|||
| — | — | (288.57) | (126.61) | (63.66) | (22.26) | (3.92) | (11.98) | (54.01) | (0.88) |
Capex/Sh
|
|||
| — | — | (2,451.02) | (3,247.29) | (1,788.90) | (1,392.80) | (526.16) | (295.20) | (441.86) | (11.91) |
Free CF/Sh
|
|||
| — | — | 4,503.06 | 4,959.32 | 1,352.32 | 466.88 | 409.31 | 427.25 | 70.86 | 1.53 |
Book Value/Sh
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Shares
|
|||
| — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | 1.63 | 0.66 | 0.44 | 0.34 | 1.12 | 1.47 | 0.10 | 0.03 |
PS Ratio
|
|||
| — | — | 3.83 | 1.06 | 1.83 | 34.09 | 2.58 | 2.29 | 1.00 | 0.00 |
PB Ratio
|
|||
| — | — | 1.52 | 0.48 | 0.57 | 0.53 | 1.06 | 1.06 | 0.30 | 0.18 |
EV/Sales
|
|||
| — | — | (6.55) | (1.17) | (1.78) | (1.56) | (1.87) | (2.37) | (0.48) | (0.58) |
EV/FCF
|
|||
| — | — | (11) | (18) | (14) | (13) | (13) | (17) | (27) | (14) |
Op' Cash Flow
|
|||
| — | — | (1) | (1) | (1) | 0 | 0 | (1) | (4) | (1) |
Capex
|
|||
| — | — | (12) | (19) | (15) | (13) | (13) | (17) | (30) | (15) |
FCF
|
|||
| — | — | 16 | 23 | 17 | 1 | 24 | 36 | 11 | 5 |
Working Cap'
|
|||
| — | — | 0 | — | 11 | 13 | 16 | 14 | 14 | 14 |
Total Debt
|
|||
| — | — | (9) | (12) | 2 | 7 | (1) | (16) | 10 | 7 |
Net Debt
|
|||
| — | — | 22 | 29 | 11 | 4 | 10 | 25 | 5 | 2 |
Sh' Equity
|
|||
| — | — | (41.70%) | (49.05%) | (52.80%) | (50.75%) | (93.88%) | (34.69%) | (61.73%) | (102.66%) |
ROA
|
|||
| — | — | (71.66%) | (64.93%) | (96.20%) | (83.37%) | (134.04%) | (113.59%) | (109.22%) | (118.79%) |
ROIC
|
|||
| — | — | (74.72%) | (81.17%) | (106.65%) | (311.44%) | (665.05%) | (95.22%) | (191.94%) | (1,620.81%) |
ROE
|
|||
Biolase, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | 0.0× | Compare |
| NUWE Nuwellis, Inc. | $2.9M | 0.0× | Compare |
| VTAK Catheter Precision, Inc. | $3.0M | 0.0× | Compare |
| XAIR Beyond Air, Inc. | $3.1M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| AFIB Acutus Medical, Inc. | $1.7M | 0.0× | Compare |
| TNON Tenon Medical, Inc. | $3.2M | 0.0× | Compare |
| PFSA PROFUSA, Inc. | $1.6M | 0.0× | Compare |
| DHAI DIH Holding US, Inc. | $1.6M | 0.0× | Compare |
Biolase, Inc. (BIOLQ) key facts
- Biolase, Inc. (BIOLQ) is a Medical Devices company in the Healthcare sector.
- Biolase, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $49.2 million, up 1.45% from fiscal 2022.
- Return on equity was −1,620.8% and debt-to-equity -3.29.
Biolase, Inc. (BIOLQ) Latest News
22 Jul
BIOLASE and MegaGen America launched a U.S. commercial collaboration to advance "More Brilliant Dentistry Together" through combined dental laser and implant solutions. U.S. commercial partnership with MegaGen America expands BIOLASE distribution and product reach in core dental markets.
25 Nov
BIOLASE, Inc. showcased its advanced YSGG laser solutions for periodontal and implant care at the Greater New York Dental Meeting (GNYDM) 2025. The company highlighted the benefits of its laser technology in enhancing dental procedures, improving patient outcomes, and providing innovative solutions for dental professionals. BIOLASE aims to strengthen its position in the dental market through these advanced offerings. The introduction of advanced laser solutions is likely to significantly enhance BIOLASE's competitive positioning and market appeal.
14 Oct
BIOLASE, Inc. showcased its innovative YSGG laser protocol for treating periodontitis at the AAP 2025 conference. This breakthrough technology aims to enhance treatment predictability and effectiveness, positioning BIOLASE as a leader in dental laser solutions. The company emphasizes the potential of this protocol to improve patient outcomes and streamline dental procedures, reflecting its commitment to advancing dental care. The introduction of a breakthrough laser protocol could significantly enhance BIOLASE's competitive positioning and market appeal in dental treatments.
10 Sep
BIOLASE, Inc. has been acquired by MegaGen Implant, positioning the company for a stronger future. The new ownership aims to enhance BIOLASE's operational capabilities and market reach, leveraging MegaGen's resources and expertise in dental implants and laser technology. This strategic move is expected to drive innovation and improve financial performance, ultimately benefiting stakeholders and customers alike. The acquisition by MegaGen Implant is a significant strategic move that could enhance BIOLASE's market position and operational capabilities.
1 Oct
BIOLASE, Inc. voluntarily initiates Chapter 11 proceedings in the United States Bankruptcy Court for the District of Delaware. The company plans to continue operating during the proceedings and is pursuing a sale process with Sonendo Inc. for $14.0 million in cash. The initiation of Chapter 11 proceedings and potential sale of assets to Sonendo Inc. are significant strategic moves that could fundamentally alter BIOLASE's trajectory and market performance.
8 Aug
BIOLASE reported strong second quarter results with 40% gross margin and over $2 million in scheduled shipments over the next twelve months. The financial results and strategic initiatives mentioned in the article are expected to significantly impact BIOLASE's future performance and market positioning.
Biolase Inc. reported a loss of $2.8 million in the second quarter, with a loss of 8 cents per share and revenue of $11.6 million. The reported loss and revenue figures may moderately influence the company's financial performance and competitive positioning.
17 Jul
SWK Holdings Corporation provided a corporate progress update and highlighted recent achievements of its borrower portfolio companies, including Biolase, Inc. Biolase, Inc. showed increased adoption of its dental laser systems, strong consumable sales, and lowered adjusted EBITDA loss, indicating significant positive impact on future performance.
18 Jun
BIOLASE, Inc. received a notice from Nasdaq for delisting due to failure to meet listing requirements. The company's common stock will be delisted from Nasdaq and will start trading on the OTC Markets Group platform under the symbol 'BIOL'. Delisting from Nasdaq and transition to OTC Markets Group platform is a significant event that could impact BIOLASE's future performance and market trajectory.
14 May
BIOLASE reported strong first quarter results with increased adoption of dental lasers and consumables, improved gross margin, and reduced adjusted EBITDA loss. The significant improvements in financial performance, operational efficiency, and growth strategy are expected to have a significant impact on BIOLASE's future trajectory and market performance.
Biolase Inc (BIOL) reports Q1 2024 earnings with revenue growth, cost savings, and market challenges. Moderately noticeable influence expected on financial performance and competitive positioning.
13 May
BIOLASE, Inc. reports 2024 first quarter results, reiterates full-year guidance for revenue growth and profitability. The financial results and guidance provided are expected to have a significant impact on BIOLASE's future performance and market positioning.
6 May
BIOLASE, Inc. to report first quarter 2024 results on May 13, 2024. The financial and operating results announcement may moderately influence BIOLASE's performance.
23 Mar
BIOLASE, Inc. beats earnings expectations with reported EPS of $-1.76 compared to expectations of $-2.56. The financial results and strategic initiatives discussed are expected to significantly impact BIOLASE's future performance and market trajectory.
22 Mar
BIOLASE reported modest revenue growth and increased lead generation in Q4 2023. They emphasized education and training initiatives to drive adoption of dental lasers. The financial results and strategic initiatives are expected to moderately influence BIOLASE's future performance.
21 Mar
BIOLASE, Inc. reports full-year 2023 results, expects continued revenue growth in 2024. The financial results and guidance provided in the article suggest significant impact on BIOLASE's future performance and market positioning.
14 Mar
BIOLASE to report Q4 and full year 2023 results on March 21, 2024. The financial and operating results announcement may moderately influence BIOLASE's performance.
22 Feb
BIOLASE, Inc. launches state-of-the-art all-tissue laser system, Waterlase iPlus Premier Edition™, at Chicago Midwinter Meeting 2024. Launch of Waterlase iPlus Premier Edition™ expected to have a significant impact on BIOLASE's future and market performance.
20 Feb
BIOLASE, Inc. launches 'Let's Talk Dental' webinar series covering various dental disciplines. The webinar series may moderately influence BIOLASE's market performance by enhancing education and awareness in laser dentistry.
15 Feb
BIOLASE, Inc. closed a $7.0 million public offering of 16,000,000 units. The significant public offering and capital raise are expected to have a major impact on BIOLASE's future financial performance and strategic positioning.
14 Feb
BIOLASE, Inc. granted extension by Nasdaq to regain compliance with stockholders' equity requirement. The extension granted by Nasdaq may moderately influence BIOLASE's financial performance and competitive positioning.
13 Feb
BIOLASE, Inc. announced pricing of $7.0 million public offering for 16,000,000 units. The public offering of $7.0 million is a significant move that could impact BIOLASE's future financial performance and market positioning.
29 Jan
BIOLASE reports unaudited revenue growth for full year 2023 and provides outlook for full year 2024. Anticipated revenue growth, cost savings, and profitability goals for 2024 indicate significant impact on Biolase's future performance.
8 Jan
BIOLASE increases dental laser courses in response to high demand, offering advanced mastery and specialized courses in 2024. The expansion of educational offerings is a significant strategic move that can impact BIOLASE's market performance and competitive positioning.
3 Jan
BIOLASE, Inc. receives second Top Workplaces 2023 award based on employee feedback survey. The award may positively impact BIOLASE's employee morale and overall company culture, potentially leading to improved performance.
14 Dec
BIOLASE, Inc. receives Top Workplaces 2023 award based on employee feedback survey. Recognition as a top workplace can positively impact employee morale and productivity, potentially leading to improved company performance.
12 Dec
BIOLASE successfully concludes trial of Waterlase iPlus All Tissue laser with positive feedback from dentists. The trial results and unanimous approval are likely to have a significant impact on BIOLASE's future market performance.
6 Dec
BIOLASE, Inc. announces pricing of $1.4 million registered direct offering priced at-the-market under Nasdaq rules. The offering is expected to have a significant impact on BIOLASE's future and market performance.
9 Nov
BIOLASE reported third quarter financial results with total revenue of $10.9 million, a 9% decrease from the previous year. Gross margin increased to 34% due to operational improvements. The company expects full year 2023 revenue to be 1 to 3% higher than 2022. The financial results and operational efficiencies are expected to moderately influence BIOLASE's performance and competitive positioning.
8 Nov
BIOLASE, Inc. announces positive 12-month clinical outcomes for REPAIR® Perio Protocol in landmark study by McGuire Institute. The study results are expected to significantly impact BIOLASE's future market performance and competitive positioning.